RecallRadar

FDA Drug recall D-0827-2026

Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by Fresenius Kabi USA, LLC, Lake Zurich, Il…

On 2026-09-02 the FDA classified a Class I recall of Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by Fresenius Kabi USA, LLC, Lake Zurich, Il… by Fresenius Kabi Usa, citing presence of particulate matter:An internal investigation at the firm found the product to contain glass particles.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0827-2026
ClassificationClass I
Statusongoing
Initiated2026-08-10
Published2026-09-02
Last updated2026-09-13 11:52 UTC
CompanyFresenius Kabi Usa
DistributionUS

Product

Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by Fresenius Kabi USA, LLC, Lake Zurich, Illinois, 60047, NDC 65219-594-20.

Reason

Presence of particulate matter:An internal investigation at the firm found the product to contain glass particles.

Identifiers

ndc65219-590-04
ndc65219-592-10
ndc65219-594-20
code_infoLot: 16UI07, Exp 08/31/2028

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0827-2026%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.